文献速递精神分裂症与精神病性障碍

18种抗精神病药对精神分裂症患者代谢功能影响的比较:系统综述与网络荟萃分析

Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis.
PubMed 文献 · Lancet Psychiatry · 2019-12-17

奥氮平和氯氮平代谢副作用最差,阿立哌唑、依匹哌唑、卡利拉嗪、鲁拉西酮和齐拉西酮最轻微。基线体重较高、男性和非白种人是代谢恶化的预测因素,精神症状改善与代谢紊乱相关。

要点

  • 奥氮平和氯氮平代谢副作用最差,阿立哌唑等五种药最轻微。
  • 基线体重较高、男性和非白种人预测代谢恶化。
  • 精神症状改善与体重、BMI、总胆固醇和LDL升高及HDL降低相关。

核心结论

  • 抗精神病药之间代谢副作用存在显著差异,奥氮平和氯氮平最差,阿立哌唑、依匹哌唑、卡利拉嗪、鲁拉西酮和齐拉西酮最轻微。
  • 基线体重较高、男性和非白种人是抗精神病药所致代谢变化的易感性预测因素。
  • 精神病理学改善与代谢紊乱相关。

研究设计与样本

  • 系统综述与频率学派随机效应网络荟萃分析,检索MEDLINE、EMBASE和PsycINFO至2019年6月30日。
  • 中位治疗时长6周(IQR 6-8)。

临床怎么用

  • 治疗指南应更新以反映上述发现。
  • 抗精神病药选择应个体化,考虑临床情况以及患者、照护者和临床医生的偏好。

局限性

  • 中位治疗时长仅6周,长期代谢影响不明确。
  • 未报告其他潜在局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antipsychotic treatment is associated with metabolic disturbance. However, the degree to which metabolic alterations occur in treatment with different antipsychotics is unclear. Predictors of metabolic dysregulation are poorly understood and the association between metabolic change and change in psychopathology is uncertain. We aimed to compare and rank antipsychotics on the basis of their metabolic side-effects, identify physiological and demographic predictors of antipsychotic-induced metabolic dysregulation, and investigate the relationship between change in psychotic symptoms and change in metabolic parameters with antipsychotic treatment. METHODS: We searched MEDLINE, EMBASE, and PsycINFO from inception until June 30, 2019. We included blinded, randomised controlled trials comparing 18 antipsychotics and placebo in acute treatment of schizophrenia. We did frequentist random-effects network meta-analyses to investigate treatment-induced changes in body weight, BMI, total cholesterol, LDL cholesterol, HDL cholesterol, triglyceride, and glucose concentrations. We did meta-regressions to examine relationships between metabolic change and age, sex, ethnicity, baseline weight, and baseline metabolic parameter level. We examined the association between metabolic change and psychopathology change by estimating the correlation between symptom severity change and metabolic parameter change. FINDINGS: Of 6532 citations, we included 100 randomised controlled trials, including 25 952 patients. Median treatment duration was 6 weeks (IQR 6-8). Mean differences for weight gain compared with placebo ranged from -0·23 kg (95% CI -0·83 to 0·36) for haloperidol to 3·01 kg (1·78 to 4·24) for clozapine; for BMI from -0·25 kg/m2 (-0·68 to 0·17) for haloperidol to 1·07 kg/m2 (0·90 to 1·25) for olanzapine; for total-cholesterol from -0·09 mmol/L (-0·24 to 0·07) for cariprazine to 0·56 mmol/L (0·26-0·86) for clozapine; for LDL cholesterol from -0·13 mmol/L (-0.21 to -0·05) for cariprazine to 0·20 mmol/L (0·14 to 0·26) for olanzapine; for HDL cholesterol from 0·05 mmol/L (0·00 to 0·10) for brexpiprazole to -0·10 mmol/L (-0·33 to 0·14) for amisulpride; for triglycerides from -0·01 mmol/L (-0·10 to 0·08) for brexpiprazole to 0·98 mmol/L (0·48 to 1·49) for clozapine; for glucose from -0·29 mmol/L (-0·55 to -0·03) for lurasidone to 1·05 mmol/L (0·41 to 1·70) for clozapine. Greater increases in glucose were predicted by higher baseline weight (p=0·0015) and male sex (p=0·0082). Non-white ethnicity was associated with greater increases in total cholesterol (p=0·040) compared with white ethnicity. Improvements in symptom severity were associated with increases in weight (r=0·36, p=0·0021), BMI (r=0·84, p<0·0001), total-cholesterol (r=0·31, p=0·047), and LDL cholesterol (r=0·42, p=0·013), and decreases in HDL cholesterol (r=-0·35, p=0·035). INTERPRETATION: Marked differences exist between antipsychotics in terms of metabolic side-effects, with olanzapine and clozapine exhibiting the worst profiles and aripiprazole, brexpiprazole, cariprazine, lurasidone, and ziprasidone the most benign profiles. Increased baseline weight, male sex, and non-white ethnicity are predictors of susceptibility to antipsychotic-induced metabolic change, and improvements in psychopathology are associated with metabolic disturbance. Treatment guidelines should be updated to reflect our findings. However, the choice of antipsychotic should be made on an individual basis, considering the clinical circumstances and preferences of patients, carers, and clinicians. FUNDING: UK Medical Research Council, Wellcome Trust, National Institute for Health Research Oxford Health Biomedical Research Centre.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2019. PMID: 31860457. doi:10.1016/S2215-0366(19)30416-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。